Ontology highlight
ABSTRACT:
SUBMITTER: Glekas AP
PROVIDER: S-EPMC4429778 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110715 8
<h4>Unlabelled</h4>Imatinib mesylate is a tyrosine kinase inhibitor that was approved by the U.S. Food and Drug Administration in 2001 for treatment of many different stages of chronic myeloid leukemia and in 2002 for treatment of gastrointestinal stromal tumors. Imatinib is known to inhibit the dysregulated proliferation of chronic myeloid leukemia, which is associated with the Bcr-Abl kinase; in gastrointestinal stromal tumors, imatinib is known to act via c-Kit kinase inhibition. The objectiv ...[more]